Want to join the conversation?
Craig Hettenbach of Morgan Stanley asks how $QRVO wants to use the cash. CEO Robert Bruggerworth said that the company expects to continue buying back shares under the $1Bil authorization program and it expects to buy back steadily. He added that $QRVO will look for acquisition opportunities that would fit well with the company.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.